Abstract
A typical feature of ageing is a chronic, low-grade inflammation characterized by a general increase in the production of proinflammatorycytokines and inflammatory markers (“inflamm-ageing”). This status may slowly damage one or several organs, especiallywhen unfavorable genetic polymorphisms and epigenetic alterations are concomitant, leading to an increased risk of frailty together withthe onset of age-related chronic diseases. The contribution of different tissues (adipose tissue, muscle), organs (brain, liver), immunesystem and ecosystems (gut microbiota) to age-related inflammation (“inflamm-ageing”) will be discussed in this review in the context ofits onset/progression leading to site-restricted and systemic effects. Moreover, some of the possible strategies and therapies to counteractthe different sources of molecular mediators which lead to the age-related inflammatory phenotype will be presented
Lingua originale | English |
---|---|
pagine (da-a) | 609-618 |
Numero di pagine | 10 |
Rivista | CURRENT PHARMACEUTICAL DESIGN |
Volume | 16 |
Stato di pubblicazione | Published - 2010 |
All Science Journal Classification (ASJC) codes
- ???subjectarea.asjc.2700.2700???
- ???subjectarea.asjc.3000.3004???
- ???subjectarea.asjc.3000.3002???